Pertuzumab: A new anti-HER2 drug in the management of women with breast cancer

Future Oncology

Volumn 11, Issue 6, 2015, Pages 923-931

  Dawood, Shaheenah ^a   Sirohi, Bhawna ^b  

^a DUBAI HOSPITAL   (United Arab Emirates)

^b Multispecialty Hospital Shaw Mazumdar Medical Centre   (India)

Author keywords

anti HER2 therapy; breast cancer; combination; docetaxel; pertuzumab; trastuzumab

Indexed keywords

CAPECITABINE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER STAGING; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; METABOLISM; METASTASIS; PATHOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84924959944     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.7     Document Type: Article

References (32)

1. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
2. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
3. Gianni L, Dafni U, Gelber RD et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12(3), 236-244 (2011).
4. Perez EA, Romond EH, Suman VJ et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. Oncol. 29(25), 3366-3373 (2011).
5. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
6. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783-1791 (2012).
7. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell. Biol. 2, 127-137 (2001).
8. Burgess AW, Cho HS, Eigenbrot C et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell. 12, 541-552 (2003).
9. Lee-Hoeflich ST, Crocker L, Yao E et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68, 5878-5887 (2008).
10. Agus DB, Akita RW, Fox WD et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2, 127-137 (2002).
11. Agus DB, Gordon MS, Taylor C et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol. 23, 2534-2543 (2005).
12. Scheuer W, Friess T, Burtscher H et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 69, 9330-9336 (2009).
13. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm. Res. 23, 1275-1284 (2006).
14. Genentech Inc. PERJETA (pertuzumab) injection for intravenous administration package insert. South San Francisco, CA (2012).www.accessdata.fda.gov/drugsatfda-docs/label/2012/125409lbl.pdf
15. Metzger-Filho O1, Winer EP, Krop I. Pertuzumab: optimizing HER2 blockade. Clin. Cancer Res. 19(20), 5552-5556 (2013).
16. Yamamoto N1, Yamada Y, Fujiwara Y et al. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn. J. Clin. Oncol. 39(4), 260-266 (2009).
17. Attard G1, Kitzen J, Blagden SP et al. A Phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br. J. Cancer 97(10), 1338-1343 (2007).
18. Portera CC, Walshe JM, Rosing DR et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin. Cancer Res. 14(9), 2710-2716 (2008).
19. Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28(7), 1138-1144 (2010).
20. Cortés J, Fumoleau P, Bianchi GV et al. Pertuzumab monotherapy after trastuzumabbased treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 30(14), 1594-1600 (2012).
21. Gianni L, Lladó A, Bianchi G et al. Openlabel, Phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28(7), 1131-1127 (2010).
22. Baselga J, Cortés J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109-119 (2012).
23. Swain SM, Kim SB, Cortés J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebocontrolled, Phase 3 study. Lancet Oncol. 14(6), 461-471 (2013).
24. Iyengar N, Datko FM, D'Andrea G et al. Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer with cardiac biomarker data (abstract). Presented at : 2013 San Antonio Breast Cancer Symposium. TX, USA, 10-14 December 2013.
25. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, Phase 2 trial. Lancet Oncol. 13(1), 25-32 (2012).
26. Schneeweiss A, Chia S, Hickish T et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline free standard regimen: a randomized Phase II study (TRYPHAENA). Presented at: 34th annual San Antonio Breast Cancer Symposium. TX, USA, 6-10 December 2011.
27. Jhaveri K, Dang C. Dual targeting of human epidermal growth factor receptor2 (HER2) in neoadjuvant trials for operable HER2 positive (HER2+) disease. Curr. Breast Cancer Rep. 5, 321-330 (2013).
28. Baselga J, Cortes J, IM S-A et al. Biomarker analyses in CLEOPATRA: a Phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Res. 72(Suppl. 3), Abstract S5-S1 (2012).
29. Cortes J, Baselga J, Im Y-H, Ross G, Clark E, Knott A et al. Quality of life assessment in CLEOPATRA, a Phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. J. Clin. Oncol. 30(15 Suppl.), 598 (2012).
30. National Cancer Network Breast Cancer Guidelines. www.nccn.org
31. Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann. Oncol. 23(3), 791-800 (2012).
32. US Food and Drug Administration. 2013 meeting materials, Oncologic Drugs Advisory Committee. www.fda.gov